Cargando…

Response criteria in solid tumors (PERCIST/RECIST) and SUV(max) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy

BACKGROUND: The purpose of this study was to evaluate the prognostic impact of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) and of pre- and post-treatment maximum Standard Uptake Value (SUV(max)) in regards to surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pierson, Cory, Grinchak, Taras, Sokolovic, Casey, Holland, Brandi, Parent, Teresa, Bowling, Mark, Arastu, Hyder, Walker, Paul, Ju, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830069/ https://www.ncbi.nlm.nih.gov/pubmed/29486779 http://dx.doi.org/10.1186/s13014-018-0980-7

Ejemplares similares

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Impact of PET reconstruction protocols on quantification of lesions that fulfil the PERCIST lesion inclusion criteria
por: Devriese, Joke, et al.
Publicado: (2018)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
por: Rendl, Gundula, et al.
Publicado: (2022)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Correlation of (18)F-FDG/PET SUV(max), SUV(mean), MTV, and TLG with HIF-1α in Patients with Colorectal Cancer
por: Kaymak, Zümrüt Arda, et al.
Publicado: (2021)

Value of SUV(max) for the Prediction of Bone Invasion in Oral Squamous Cell Carcinoma
por: Stalder, Stephanie A., et al.
Publicado: (2020)

Pretreatment SUV(max) predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
por: Horne, Zachary D, et al.
Publicado: (2014)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Assessment of Mediastinal Tumors Using SUV(max) and Volumetric Parameters on FDG-PET/CT
por: Morita, Takahiro, et al.
Publicado: (2017)

Utility of SUV(max) on (18) F-FDG PET in detecting cervical nodal metastases
por: Lim, Rebecca S. M., et al.
Publicado: (2016)

EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program
por: Lasnon, Charline, et al.
Publicado: (2017)

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer
por: Whisenant, Jennifer G., et al.
Publicado: (2020)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv(max)) In Laryngeal and Hypopharyngeal Cancer
por: Werner, Jonas, et al.
Publicado: (2019)

Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
por: Ziai, D., et al.
Publicado: (2013)

Prognostic value of nodal SUV(max) of (18)F-FDG PET/CT in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy
por: Lee, So Jung, et al.
Publicado: (2017)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

Deformation Effect on SUV(max) Changes in Thoracic Tumors Using 4-D PET/CT Scan
por: Huang, Tzung-Chi, et al.
Publicado: (2013)

Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
por: Yaprak, Gokhan, et al.
Publicado: (2019)

Prognostic Prediction of BRCA Mutations by (18)F-FDG PET/CT SUV(max) in Breast Cancer
por: Özdemir, Semra, et al.
Publicado: (2021)

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST
por: Depardon, Edouard, et al.
Publicado: (2018)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k4jtmih9bocj50g6ah4m3mh8cd